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1. Introduction
Chronic tissue damage often results in a deregulated wound
healing, characterized by an imbalance between extracellular
matrix (ECM) synthesis (¢brogenesis) and degradation (¢bro-
lysis), that leads to scar formation. Excessive scarring ¢nally
results in architectural distortion and failure of organs such as
lungs, kidneys and liver. Hepatic stellate cells (HSC) have
been identi¢ed as an important cellular source of ECM in
liver ¢brosis [1]. These cells reside in the perisinusoidal space
of Disse that separates hepatocytes from the sinusoidal endo-
thelium. Upon injury (e.g. by toxins or chronic hepatitis) the
normally quiescent HSC become activated and start to pro-
liferate. The activated HSC undergo a phenotypic transdi¡er-
entiation to contractile myo¢broblasts (MFB) that express
K-smooth muscle actin and an excess of ECM molecules.
2. Relevance of TGFL1 in ¢brosis
Cytokines of the transforming growth factor (TGF) family
in£uence a wide spectrum of cellular processes including dif-
ferentiation, proliferation, apoptosis and migration. In most
cells TGFL1 has anti-proliferative activity and is the most
potent single pro¢brogenic factor known. TGFL1 participates
in initiation and maintenance of ¢brogenesis in many organs
including the liver. Accordingly, tissue and serum levels of
active TGFL1 are elevated in ¢brosis, and overexpression of
TGFL1 in transgenic mice and application of exogenous
TGFL1 can induce organ ¢brosis [2,3]. Furthermore, experi-
mental ¢brosis can be inhibited by anti-TGFL1 treatments,
e.g. with neutralizing antibodies or soluble TGFL receptors
[4,5]. The observed TGFL1 expression of activated HSC/
MFB, the potency of TGFL1 to upregulate ECM expression,
and the expression of TGFL receptors on HSC has led to a
widely accepted model in which persistent auto-/paracrine
stimulation of activated HSC/MFB by TGFL1 is the key ¢-
brogenic response in liver ¢brosis. Other cellular sources for
TGFL1 in liver are hepatocytes, (sinusoidal) endothelial cells,
platelets, and in¢ltrating mononuclear cells. Since speci¢c in-
hibition of TGFL1 seems to be a promising target for an anti-
¢brotic therapy, the underlying molecular mechanisms of the
pro¢brogenic e¡ects of TGFL1 are the focus of intense inves-
tigations.
3. TGFL1-induced signal transduction
TGFL1 is synthesized as a precursor (latent TGFL1) that
has to undergo speci¢c proteolysis, e.g. by plasmin, and dis-
sociation from the latency-associated peptide moiety for acti-
vation. Our understanding of TGFL-dependent signal trans-
duction has been revolutionized in the past few years (see [6]
for review). Binding of active TGFL1 to the cellular, consti-
tutively phosphorylated TGFL type II receptor (TGFLRII)
induces formation of heterotetrameric complexes with type I
receptors (TGFLRI) (Fig. 1A). Upon phosphorylation of ser-
ine and threonine residues in TGFLRI by ligand-activated
TGFLRII the thereby activated serine/threonine kinase do-
main of TGFLRI phosphorylates the TGFL-speci¢c signal
transducers Smad2 and Smad3. Whereas Smad2 requires pre-
sentation to TGFLRI by the adapter protein Smad anchor for
receptor activation (SARA), Smad3 works SARA-indepen-
dent. Phosphorylated Smad2 and Smad3 dissociate from the
(receptor) complex and form heterodimeric complexes with
Smad4 or heterotrimeric complexes with Smad3 and Smad4.
These complexes translocate into the nucleus where they act
as transcriptional modulators on TGFL responsive gene pro-
moters, e.g. those for plasminogen activator inhibitor 1 (PAI-
1), the K2 chain of collagen I, and Smad7 [7]. Smad2 seems to
be the main signaling molecule for TGFL1-induced ECM up-
regulation, since ¢broblasts from Smad3 knockout mice still
increase their ECM molecule production upon TGFL1 treat-
ment. A Smad2 gene inactivation is embryonically lethal [7].
The third TGFL receptor (TGFLRIII or betaglycan) is a pro-
teoglycan that binds TGFL1 with high a⁄nity, serving as a
non-signaling co-receptor for TGFLRI and TGFLRII. Ex-
pression of TGFLRIII on the cell surface seems to be down-
regulated during transdi¡erentiation of HSC to MFB [8].
4. Distinct TGFL1 binding by HPCs and myo¢broblasts?
Stimulation by TGFL1 requires binding of the cytokine to
its cognate receptors on activated HSC/MFB and subsequent
signal transduction to the nucleus. Investigations of the bind-
ing properties of HSC and MFB for TGFL1 led to divergent
results. Using HSC isolated from liver subsequent to injection
of the hepatotoxin CCl4, constant cellular TGFL1 binding
within the following 72 h was observed [9]. Cells exhibited
an increased secretion of the ECM protein ¢bronectin and
its synthesis could be further stimulated by exogenous
TGFL1. HSC cultured on plastic undergo spontaneous acti-
vation and start to transdi¡erentiate to MFB within 3^5 days.
Using 5 day old culture-activated cells Friedman et al. found
elevated and saturable TGFL1 binding compared to HSCs
maintained in suspension to prevent spontaneous activation
[10]. Fibronectin mRNA expression was only inducible by
TGFL1 in culture-activated HSC, whereas suspension cul-
tured cells showed no response. However, how far HSC
held in suspension can substitute for quiescent, normally ad-
herent HSC has to be discussed.
Somewhat in contrast, Dooley et al. observed high binding
0014-5793 / 01 / $20.00 ß 2001 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 1 ) 0 2 6 5 5 - 2
FEBS 25066 23-7-01
FEBS 25066 FEBS Letters 502 (2001) 1^3
of TGFL1 to short-term cultured (2^3 days) ‘quiescent’ HSC
and an almost absent binding to MFB (one passage) that had
been cultured for v10 days [8]. Although the TGFL1 binding
decreased, the mRNA levels and protein expression of
TGFLRI and TGFLRII increased during early activation of
HSC and remained high in MFB. The reduced ability of acti-
vated HSC/MFB to bind TGFL1 was paralleled by a strongly
decreased response to the anti-proliferative e¡ects and tran-
scriptional activation of TGFL1 for Smad7 and the ECM
molecules hyaluronan and collagen K2(I). Fully transdi¡eren-
tiated MFB generated by long term cultivation on plastic or
isolated from ¢brotic liver showed a constitutive and TGFL1-
independent high expression of collagen I, the major ECM
component involved in ¢brogenesis.
5. TGFL1 signaling in HPCs and myo¢broblasts
In this issue of the journal Dooley et al. present a more
detailed analysis of the TGFL1 signaling in quiescent HSC
(cultured for only 2 days) and MFB [11]. In TGFL1 respon-
sive 2 day cultured quiescent HSC, phosphorylation and nu-
clear translocation of Smad2 was induced by exogenous
TGFL1, whereas this event was reduced in culture-activated
HSC (7 days) and absent in MFB. TGFL1 also induced phos-
phorylation of Smad3 in quiescent HSC, but not in MFB.
Since Western blot analysis demonstrated comparable protein
expression of Smad2 and Smad3 both in quiescent HSC and
MFB, the absence of phosphorylated Smad2 and Smad3 in
MFB provides further evidence for reduced TGFL1 binding to
its receptors or a postreceptor blockade in MFB. A low re-
sponse to TGFL1 was also reported for CFSC-2G cells, an
activated HSC line derived from a cirrhotic rat liver display-
ing a high constitutive expression of ECM proteins [12]. Since
in CFSC-2G cells ECM production could be further stimu-
lated by TGFL1, they might not be fully activated HSC. Ac-
cordingly, TGFL1 induced phosphorylation, subsequent nu-
clear translocation of Smad2 and transcriptional activation
of ECM promoters. However, in untreated CFSC-2G cells
Smad3 was constitutively phosphorylated and already present
in the nucleus.
Transfecting MFB with a recombinant adenovirus encoding
a constitutively active TGFLRI Dooley et al. completely re-
stored TGFL1 signaling [11]. In these modi¢ed MFBs phos-
phorylated Smad2 and transcriptional activation of a Smad
responsive promoter were clearly detectable, demonstrating
that the downstream signaling is functional in MFB. Conse-
quently, the di¡erent TGFL1 response of quiescent HSC and
MFB appears to be caused by a variant activity of their TGFL
receptors. Recent investigations using modi¢ed mink lung
epithelial cells (Mv1Lu-DR26) expressing a kinase-domain
mutated and functionally inactive TGFLRII indicated that
growth inhibitory and transcription regulatory roles of
TGFL1 might be signaled independent of each other [13]. In
these cells TGFL1 failed to inhibit proliferation and to up-
regulate the cyclin-dependent kinase inhibitor p15INK4B, while
transcriptional activation of the TGFL1 responsive promoter
of a pro¢brogenic protein (PAI-1) was not a¡ected. On the
other hand, mutations in the TGFLRI have been de¢ned that
only block the growth inhibitory e¡ects of TGFL1, while tran-
scriptional activation of PAI-1 and ¢bronectin remains unaf-
fected [14]. In summary these results suggest a major role of
TGFLRII in the regulation of ECM gene expression, while
TGFLRI appears to mainly transduce regulatory e¡ects of
TGFL1 on proliferation.
In exploring the fate of the TGFL receptors after ligand
binding, Zwaagstra et al. found that downregulation of cell
surface TGFL receptors was due to internalization. This
downregulation is a cooperative event with participation of
Fig. 1. Scheme of TGFL1 signaling. A: TGFL1 that underwent acti-
vation binds to TGFL receptors TGFLRII (RII) and TGFLRIII
(RIII, step 1). Upon ligand binding TGFLRII forms a heterotetra-
meric complex with TGFLRI wherein the constitutively active ser-
ine/threonine kinase of TGFLRII phosphorylates and thereby acti-
vates TGFLRI (step 2). The activated TGFLRI now phosphorylates
the TGFL-speci¢c signal transducer Smad2, which is recruited and
presented by SARA, the SARA (step 3). Smad3 can substitute for
the Smad2/SARA complex (not shown). Phospho-Smad2 and
SARA separate and after assembling with Smad4 the formed com-
plex translocates into the nucleus where it cooperates with transcrip-
tional activators or repressors to modulate transcription of TGFL1
responsive genes (step 4). B: Hypothetical alternative signaling path-
way for the growth inhibitory e¡ect of TGFL1. After TGFL binding
the receptors TGFLRI and TGFLRII or TGFLRI, TGFLRII and
TGFLRIII form heteromeric complexes that further aggregate on
the cell surface (step 1 and 2). The receptor(s) enter the cell with or
without bound ligand (not known) by a mechanism distinct from
normal endocytosis via clathrin-coated vesicles. TGFLRI translo-
cates into the nucleus where it might in£uence cell cycle regulation.
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all three receptors and consisting of two phases: the receptor
complexes ¢rst form aggregates on the cell surface, followed
by internalization by a mechanism that is distinct from nor-
mal endocytosis via clathrin-coated vesicles [15,16]. Receptor
internalization was prevented when ligand binding took place
at 4‡C and subsequent warming to 37‡C decreased cell surface
bound TGFL1. Since the authors show that this observation
was not caused by internalization of TGFL1, they hypothe-
sized that TGFL receptor aggregation could lead to decreased
receptor a⁄nity.
The signal transduction mechanism underlying the TGFL1-
induced growth arrest is still not completely understood. Sur-
prisingly, in immunohistochemistry the majority of TGFLRI
was found intracellularly and accumulated in the nucleus after
TGFL1 treatment [17]. Since the cell cycle (cyclin-dependent
kinase) inhibitor olomoucine also induced nuclear localization
of TGFLRI, it might be speculated that signaling of growth
arrest is conferred by TGFLRI translocation into the nucleus
(Fig. 1B). Thus ligand-induced receptor downregulation and
reduced receptor a⁄nity, apart from altered receptor stoichi-
ometry, could be an explanation for a decreased TGFL bind-
ing to and responsiveness of MFB compared to quiescent
HSC [18].
6. Time to change paradigms?
In summary, the results presented by Dooley et al. [8,11]
demonstrate a TGFL1 insensitivity of MFB that strongly ar-
gues against the continuous auto-/paracrine stimulation of
these cells by TGFL1, as postulated by the currently accepted
model of ¢brogenesis. The authors provide strong evidence
that the lost TGFL1-sensitivity of MFB results from altered
properties of the (signaling) TGFL receptors. Nonetheless,
TGFL1 still plays a pivotal role in the pathogenesis of organ
¢brosis, especially in liver. Although apparently not directly
a¡ecting MFB, TGFL1 can induce activation of quiescent
HSC and their subsequent transdi¡erentiation to MFB. Fur-
thermore, continuous TGFL1 secretion of MFB supports
spreading of the ¢brogenic reaction into previously una¡ected
tissue areas. A currently unresolved problem is how the
TGFL1-insensitive MFB manage to stay activated. Other pro-
¢brogenic factors, e.g. platelet-derived growth factor (PDGF),
basic ¢broblast growth factor (FGF-2), and endothelin-1 may
preserve MFB activation. However, interpretation of the
available experimental data on HSC activation requires cau-
tion, since this process was mainly studied in vitro using cul-
ture-activated cells. Activation of HSC and the resultant MFB
phenotype may di¡er signi¢cantly in vivo and in vitro, as
exempli¢ed by divergent expression of some HSC activation
markers [19,20]. In addition, a recently performed proteome
analysis of quiescent HSC, in vivo activated rat HSC/MFB
isolated from ¢brotic liver, and in vitro activated HSC/MFB
revealed non-matching protein expression changes in about
40% of identi¢ed proteins (n = 43) between in vivo and in vitro
activated HSC [21]. Therefore, future e¡orts will have to focus
on those events that most reliably represent the in vivo ¢bro-
genic activation.
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